THELIN Film-coated tablet Ref.[9316] Active ingredients: Sitaxentan

Source: European Medicines Agency (EU)  Revision Year: 2011  Publisher: Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom

Product name and form

Thelin 100 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet.

Capsule shaped yellow-to-orange film-coated tablets, debossed with T-100 on one side.

Qualitative and quantitative composition

Each film-coated tablet contains 100 mg sitaxentan sodium.

Excipients: Also contains 166.3mg of lactose monohydrate.

For a full list of excipients, see section 6.1.

Active Ingredient Description
Sitaxentan

Sitaxentan is a potent (Ki 0.43 nM) and highly selective ETA antagonist (approximately 6,500-fold more selective for ETA as compared to ETB). Endothelin-1 (ET-1) is a potent vascular paracrine and autocrine peptide in the lung, and can also promote fibrosis, cell proliferation, cardiac hypertrophy, and remodelling and is pro-inflammatory. ET-1 actions are mediated through endothelin A (ETA) and endothelin B receptors (ETB). ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension (PAH), as well as other cardiovascular disorders and connective tissue diseases.

List of Excipients

Tablet core:

Cellulose, microcrystalline (E460)
Lactose monohydrate
Hypromellose (E464)
Sodium starch glycolate
Magnesium stearate (E470b)
Disodium phosphate, anhydrous (E339)
Ascorbyl palmitate (E304)
Disodium edetate
Monobasic sodium phosphate (E339)

Film coat:

Stearic acid (E570b)
Hypromellose (E464)
Cellulose, microcrystalline (E460)
Titanium dioxide (E171)
Yellow iron oxide dehydrate (E172)
Red iron oxide dehydrate (E172)
Talc (E553b)

Pack sizes and marketing

PVC/ACLAR/paper-backed aluminium blisters containing 14 tablets.
Cartons contain 14, 28, 56, or 84 tablets.
High-density polyethylene (HDPE) bottles containing 28 tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom

Marketing authorization dates and numbers

EU/1/06/353/001
EU/1/06/353/002
EU/1/06/353/003
EU/1/06/353/004
EU/1/06/353/005

10 August 2006

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.